Arbutus Biopharma — Third Quarter 2026 Earnings Summary

Arbutus Biopharma reported a net income of $59.1 million for the third quarter of 2026, driven by a $67.3 million cash dividend from Genevant and a $178.4 million settlement payment from Moderna. The company returned $230 million to shareholders through a tender offer in early October 2026, purchasing 46 million shares at $5.00 per share. Arbutus expanded its patent infringement litigation against Pfizer and BioNTech by filing new lawsuits in Japan and amending a Canadian case, while the FDA lifted a clinical hold on its oral PD-L1 inhibitor, AB-101. Additionally, the company highlighted positive Phase 2a clinical data for its RNAi therapeutic imdusiran, which achieved functional cures in eight hepatitis B patients.